Literature DB >> 19233169

Short and long-term tumor cell responses to Aurora kinase inhibitors.

Megan R Dreier1, Aaron Z Grabovich, Jamie D Katusin, William R Taylor.   

Abstract

Aurora kinases are essential for mitosis and are candidate targets of novel chemotherapeutic agents. The inhibitors ZM447439, MK-0457 (VX-680) as well as Hesperadin have been used to dissect the roles of Aurora kinases in the cell cycle and have been tested clinically for the treatment of cancer. Here we have carried out a detailed kinetic analysis of two isogenic cell lines differing in p53 function and have compared the effects of ZM447439 and VE-465 (related to MK-0457). We find that p53 is needed for efficient cell cycle arrest when Aurora kinases are inhibited by either ZM447439 or VE-465. However, the p53-induced cell cycle block is neither immediate nor absolute. ZM447439 induced the localized accumulation of gammaH2A.X indicating that p53 induction by this drug occurs in response to DNA damage. Our analysis of the long-term effects of ZM447439 indicates that cells can evade killing by the drug, but not via a classical drug-resistance mechanism. Several mechanisms to explain how cells may evade killing by Aurora kinase inhibitors are described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233169     DOI: 10.1016/j.yexcr.2009.02.008

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  20 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

3.  Role of senescence and mitotic catastrophe in cancer therapy.

Authors:  Richa Singh; Jasmine George; Yogeshwer Shukla
Journal:  Cell Div       Date:  2010-01-21       Impact factor: 5.130

4.  Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Authors:  Ami V Patel; David Eaves; Walter J Jessen; Tilat A Rizvi; Jeffrey A Ecsedy; Mark G Qian; Bruce J Aronow; John P Perentesis; Eduard Serra; Timothy P Cripe; Shyra J Miller; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

5.  VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.

Authors:  Yan Li; Zhong-Fa Zhang; Jindong Chen; Dan Huang; Yan Ding; Min-Han Tan; Chao-Nan Qian; James H Resau; Hyung Kim; Bin Tean Teh
Journal:  Am J Transl Res       Date:  2010-05-20       Impact factor: 4.060

6.  Induction of p21CIP1 protein and cell cycle arrest after inhibition of Aurora B kinase is attributed to aneuploidy and reactive oxygen species.

Authors:  Geeta Kumari; Tanja Ulrich; Michael Krause; Florian Finkernagel; Stefan Gaubatz
Journal:  J Biol Chem       Date:  2014-04-29       Impact factor: 5.157

7.  Regulation of sororin by Cdk1-mediated phosphorylation.

Authors:  Megan R Dreier; Michael E Bekier; William R Taylor
Journal:  J Cell Sci       Date:  2011-09-01       Impact factor: 5.285

8.  Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.

Authors:  Linda Vidarsdottir; Gudridur Steingrimsdottir; Sigridur Klara Bodvarsdottir; Helga Margret Ogmundsdottir; Jorunn Erla Eyfjord
Journal:  Invest New Drugs       Date:  2010-10-20       Impact factor: 3.850

9.  Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Authors:  Jennifer M Sahni; Sylvia S Gayle; Kristen L Weber Bonk; Leslie Cuellar Vite; Jennifer L Yori; Bryan Webb; Erika K Ramos; Darcie D Seachrist; Melissa D Landis; Jenny C Chang; James E Bradner; Ruth A Keri
Journal:  J Biol Chem       Date:  2016-09-20       Impact factor: 5.157

Review 10.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.